London · Delayed Price · Currency is GBP · Price in USD Aerovate Therapeutics Statistics
Total Valuation
LON:0A2P has a market cap or net worth of GBP 2.60 billion. The enterprise value is 7.65 billion.
| Market Cap | 2.60B |
| Enterprise Value | 7.65B |
Important Dates
The last earnings date was Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -4.92% |
| Shares Change (QoQ) | -5.31% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 362.64M |
Valuation Ratios
The trailing PE ratio is 62.73 and the forward PE ratio is 17.18.
| PE Ratio | 62.73 |
| Forward PE | 17.18 |
| PS Ratio | 0.72 |
| PB Ratio | -3.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 184.78 |
| EV / Sales | 2.06 |
| EV / EBITDA | 9.19 |
| EV / EBIT | 19.93 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.16
| Current Ratio | 1.16 |
| Quick Ratio | 1.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | 6.76 |
| Debt / FCF | n/a |
| Interest Coverage | 1.06 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 4.02% |
| Return on Invested Capital (ROIC) | 4.88% |
| Return on Capital Employed (ROCE) | 7.68% |
| Revenue Per Employee | 165,074 |
| Profits Per Employee | 1,900 |
| Employee Count | 21,784 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 98.64 |
Taxes
In the past 12 months, LON:0A2P has paid 19.22 million in taxes.
| Income Tax | 19.22M |
| Effective Tax Rate | 72.72% |
Stock Price Statistics
The stock price has decreased by -16.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -16.57% |
| 50-Day Moving Average | 6.04 |
| 200-Day Moving Average | 6.59 |
| Relative Strength Index (RSI) | 59.64 |
| Average Volume (20 Days) | 43,514 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.97 |
Income Statement
In the last 12 months, LON:0A2P had revenue of GBP 3.60 billion and earned 41.39 million in profits. Earnings per share was 0.10.
| Revenue | 3.60B |
| Gross Profit | 1.29B |
| Operating Income | 371.07M |
| Pretax Income | 26.43M |
| Net Income | 41.39M |
| EBITDA | 765.66M |
| EBIT | 371.07M |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
The company has 817.36 million in cash and 5.44 billion in debt, giving a net cash position of -4.63 billion.
| Cash & Cash Equivalents | 817.36M |
| Total Debt | 5.44B |
| Net Cash | -4.63B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -783.43M |
| Book Value Per Share | -2.67 |
| Working Capital | 139.11M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 35.77%, with operating and profit margins of 10.32% and 1.15%.
| Gross Margin | 35.77% |
| Operating Margin | 10.32% |
| Pretax Margin | 0.74% |
| Profit Margin | 1.15% |
| EBITDA Margin | 21.29% |
| EBIT Margin | 10.32% |
| FCF Margin | n/a |
Dividends & Yields
LON:0A2P does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.92% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.59% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0A2P has an Altman Z-Score of 0.34 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.34 |
| Piotroski F-Score | 4 |